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Abstract
Background: Cleome gynandra L. (Capparaceae) is an edible weed used in Uganda topically for its presumed
antifungal activity against Tinea capitis. The goal of this study was to determine if this plant possesses antifungal
activity in vitro, since T. capitis is a pervasive infection among especially rural children.
Methods: Antifungal activity assay was performed by Broth dilution method, and testing done on clinical isolates
of three common Tinea capitis-causing fungal strains. Evaluation of in vitro antifungal activity of the ethanol and
water extracts of C. gynandra was done to determine the minimum inhibitory concentrations (MICs) and the
minimum fungicidal concentrations (MFCs) of the extracts.
Results: The MIC of C. gynandra ethanol extract ranged from 0.0313 to 0.0625 mg/ml for Trichophyton rubrum, and
from 0.25 to 0.5 mg/ml for both Microsporum canis and Trichophyton mentagrophytes. The MICs of C. gynandra
aqueous extract ranged between 0.125 to 0.25 mg/ml for T. rubrum, and 0.25 to 0.5 mg/ml for both M. canis and T.
mentagrophytes. T. rubrum was more sensitive than M. canis (p < 0.002) and more sensitive than T. mentagrophytes
(p < 0.035) to the antifungal activity of C. gynandra. T. rubrum was 6.9 times (95 % CL: 1.15 – 41.6) more likely to
have a better outcome (more sensitive) than T. mentagrophytes. Cleome gynandra aqueous extract had MFC of ≥0.
0313 mg/ml for M. canis, ≥0.0156 mg/ml for T. mentagropyhtes, and ≥0.0625 mg/ml for T. rubrum. Cleome gynandra
ethanol extract showed MFCs of ≥0.5 mg/ml for M. canis and T. mentagrophytes, and ≥0.125 mg/ml for T. rubrum.
Conclusion: Both plant extracts demonstrated antifungal activity, shown by the MIC and MFC for the different
extracts, which varied with the type of organism of the clinical fungal isolates. The ethanol extract exhibited
comparable antifungal activity to the aqueous extract indicated by the MIC values seen. Conversely, after subculturing
the fungal isolates, MFCs were lower for the aqueous than for the ethanol extract.
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Background
Many herbal products are presumed to have antifungal
properties but few scientific studies have been done to
validate these claims [1]. Cleome gynandra is one such
plant assumed to cure Tinea capitis. Cleome gynandra L.
(Isogi in the Rufumbira language, Uganda; Eshogi in the
Runyankole/Rukiga language, Uganda, and Akeo in
Lango, Uganda), also known as African Spider flower,
African Cabbage, and Dog Mustard, is an angiosperm
that belongs to the family Capparaceae. Shoots and
leaves of C. gynandra are crushed and used topically in
southwestern and northern Uganda for management of
Tinea captitis [2, 3] and also eaten as a vegetable food
[3–5]. Other medicinal uses of C. gynandra include the
treatment of migraine headache and epilepsy [6]; stom-
ach ache [3]; ear pain and sepsis, diphtheria, vomiting,
promotion of labor at the end of pregnancy, [7]; and
snake bite [8]. The mature plant is a herb that grows to
about 1.3 m with leaves that are compound (palmitate
leaves) with five leaflets (why it is called African Spider
plant). Its flowers are hermaphrodite, having both male
(androceum) and female (gynandroceum) organs thus
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acquiring the name Gynandropsis – gynophore (female)
and androphore (male). Cleome gynandra has thus also
been called Gynandropsis gynandra L. Its flowers are
regular (actinomophic), sometimes zygomorphic, hyp-
ogynous or perigynamous, and bisexual [9].
Tinea capitis is one of the most pervasive fungal infec-
tions in the population, mainly among children of school
age below 12 years, and is prevalent in adults whose im-
munity has been suppressed [10]. Current treatment op-
tions include both topical and oral agents including
clotrimazole, miconazole, nystatin, griseofluvin, and ter-
binafine. These drugs are expensive for most of the rural
poor and have many side effects, yet many plants with
medicinal activity probably exist. Many plants contain
chemicals of medicinal value (secondary metabolites
such as alkaloids, natural phenols, terpenoids, flavonoids
and antibiotics) that are precursors of medicines. The
largest rural populations in areas of developing countries
[11, 12] use these plants, or their parts, for their pre-
sumed antifungal, antibacterial, antiviral, anthelmintic,
and antimalarial activities. Some medicinal plants are
known to treat fungal infections for example Candida
albicans; Black walnut and Chamomile have been used
to treat C. albicans. The tea tree has been used to treat
athlete’s foot [13].
A number of plants are accordingly currently used in
traditional medicine to treat diverse fungal infections.
Some plants have been identified for the treatment of
opportunistic infections, including oral fungal infections
in HIV patients [6, 14]. Studies done in Tanzania on
some Combretaceae and other families of plants indicate
the possibility of obtaining plants with clinically useful
antifungal activity, particularly against C. albicans and
other yeast-like fungi [15]. Other plants studied in East
Africa have been shown to have antifungal activity of
varying amounts [6, 16]. These herbal treatments applied
by traditional healers and rural populations need to be
documented scientifically for their safety and efficacy,
and feedback given to the community. Therefore, the
present study was conducted to determine the in vitro
antifungal activity of Cleome gynandra, a plant locally
used for the treatment of Tinea capitis in children, given




This was a controlled experimental in vitro study carried
out at both the Pharmacy Laboratory and the Mycology
Unit of the Microbiology laboratory at Mbarara Univer-
sity of Science and Technology. Three clinical fungal
isolates, namely, Microsporum canis, Trichophyton
rubrum and Trichophyton mentagrophytes were obtained
from the Mycology Department of Mbarara Regional
Referral Hospital. The fungal isolates had not lasted
more than 3 months in the laboratory.
Identification, collection and drying of Cleome gynandra
Fresh aerial plant parts (shoots, leaves, flowers and fresh
pods) believed to have antifungal activity against Tinea
capitis were collected from cultivated lands around
Mbarara University of Science and Technology (MUST)
and taken for botanical identification at the Faculty of
Science, MUST. The plant was identified by Dr. Eunice
A. Olet, a taxonomist at the Department of Biological
Sciences, Faculty of Science, MUST, and given a herbar-
ium number, IMANIRAMPA001. A herbarium specimen
was prepared and deposited at the Department of Bio-
logical Sciences. The collected and identified plant mate-
rials were brought to the laboratory, washed with fresh
distilled water, cut into small pieces, and air-dried under
shade at room temperature. The dried plant materials
were crushed into small pieces and blended using a port-
able electric blender to reduce them into powder form,
and weight of the powder taken.
Extraction
Extraction was done with ethanol using the Soxhlet ex-
tractor, and by cold maceration with fresh distilled
water.
Soxhlet extraction
A predetermined amount of the dried plant powder was
put in a Soxhlet apparatus to which enough ethanol
(70 % v/v) was added to submerge the powder and con-
tinuously extract it, until the extracting solvent became
clear in the thimble indicating that the extraction of the
phytochemicals soluble in the solvent ethanol was
complete. The volume was noted; the extract was dried
in an oven at a temperature of 70 °C centigrade, and the
weight of the dry ethanol extract taken. The residue after
the ethanol extraction process was dried for further ex-
traction by cold maceration using fresh, cool, distilled
water.
Cold maceration
Extraction of the plant material was done using macer-
ation as the appropriate method because when used as a
phytomedicine, Cleome gynandra is applied to the af-
fected scalp in the raw form, since it is believed that
heating may inactivate the ingredients. The dried herbal
material (after ethanol extraction) was recrushed into
powder by use of a portable electric blender, its weight
taken, then transferred into a glass vessel to which
enough volume of the extracting solvent water was
added until the medicinal plant residues were fully
immersed. The vessel was closed with a tight-fitting
glass cover and the contents in the vessel were shaken
Imanirampa and Alele BMC Complementary and Alternative Medicine  (2016) 16:194 Page 2 of 8
after every 4 h except at night, and left to stand for three
days (72 h) but with subsequent agitation until this
period was over. The contents of the flask were then
strained through two clean pieces of cotton cloth placed
on top of filter paper, both supported by a funnel, and
the extracted solution (miscella) collected in a flask with
a tight-fitting cover. The maximum yield of water extract
was obtained by squeezing the marc (solid residue) in
the top clean dry piece of cloth, while drippings of liquid
extract were allowed to pass through the second clean
dry piece of cloth, to the contents of the flask through
Whatman’s filter paper. The volume of the yield was
noted. Both the ethanol and water extracts were trans-
ferred to a hot-air oven for drying at temperatures be-
tween 50 °C and 70 °C, and later transferred into a
desiccator for further drying.
Phytochemical screening
Phytochemical screening of the extracts for secondary
metabolites was done according to standard methods
[11]. Briefly, general chemical composition of the plant
was determined by means of chemical qualitative ana-
lysis on the aerial plant extracts obtained through ex-
traction with solvents of increasing polarity, that is,
ethanol (70 % v/v), and water, respectively. The phyto-
chemical screening for secondary metabolites was car-
ried out at the Pharmacy laboratory of MUST. Oils and
fats were tested by adding one ml of Sudan III diluted
with equal volume of water, adding a small quantity of
each extract, and heating the mixture on a water bath
until the solvent evaporated; a red color was observed
for fat globules present in the mixture. Alkaloids were
tested by adding a small quantity of each extract (etha-
nolic and aqueous) to a test tube and stirring with 5 mL
of 1 % hydrochloric acid for five minutes on a water
bath, and then filtering (Dragendorff ’s test). To the fil-
trate of each extract, a few drops of Dragendorff ’s re-
agent were added and then observed for the formation
of a reddish-brown precipitate. Steroids were tested by
dissolving small amounts of each extract in 1 ml of
chloroform; 2 ml of acetic anhydride were added and
mixed thoroughly, then a few drops of concentrated
sulphuric acid were added from the sides of the test tube
without shaking, and the solution observed for the for-
mation of a brown ring at the junction of the two layers
(Liebermann-Burchard’s test). Terpenoids were tested as
follows: to the portion of each extract, two ml of chloro-
form was added and then a few drops of concentrated
sulphuric acid added from the sides of the test tube
without shaking and the solution observed for the for-
mation of a deep red color indicating the presence of
terpenoids (Salkowski’s test). Sugars were tested using
Fehling’s test: a small quantity of each extract was hy-
drolyzed by boiling with 5 ml of dilute hydrochloric acid
and the resulting solution neutralized with sodium hy-
droxide solution. To each of these solutions, a few drops
of Fehling’s solution were added, each heated on a water
bath for 2 min, and observed for the formation of a
brick-red precipitate. Tannins were tested using the fer-
ric chloride test. Small quantities of each extract were
boiled in 10 ml of distilled water and then filtered. Few
drops of 1 % ferric chloride solution were added to 2 ml
of each filtrate and observed for green color changes.
Lastly, flavonoids were tested using the lead acetate test
in which a small quantity of each extract was added to
2 ml of lead acetate. A positive test was indicated by the
formation of a precipitate.
Antifungal bioassay
Selection of fungal strains
Fungal strains selected for the antifungal bioassays were
clinical isolates of Microporum canis, Trichophyton
rubrum, and Trichophyton mentagrophytes obtained from
the Mycology Department of MUST as dermatophytic
fungi causing Tinea capitis.
Test isolates
Clinical isolates of M. canis, T. rubrum, and T. menta-
grophyte were identified using Lactophenol Cotton Blue
Staining (LPCB) technique, based on their morpho-
logical structures including micro-conidia and macro-
conidia. The pure vegetative colonies of test isolates
were subcultured onto SDA slants incubated at 30 °C for
7 days and observed for growth. Two slants per fungal
species were prepared. These slants were considered for
the initial inocula. Using the tip of a sterile applicator
stick, pure colonies of M. canis, T. mentagrophyte and T.
rubrum each respectively, were picked and added to 5
mls of 0.85 % sodium chloride, and the resultant suspen-
sion was vortexed for 15–20 s and later adjusted to a 3.0
McFarland standard turbidity. Two hundred microliters
(200 μl) of each fungal suspension were mixed separately
with the plant extracts in their RPMI 1640 serial dilu-
tions. Eight (8) tubes for each fungal suspension contain-
ing the plant extract dissolved in RPMI 1640 and
chloramphenicol (40 μl), were arranged in descending
order of their concentrations (0.5 mg/ml, 0.25 mg/ml,
0.125 mg/ml, 0.0625 mg/ml, 0.0313 mg/ml, 0.0156 mg/
ml, 0.00781 mg/ml, and 0.00391 mg/ml). Two other
tubes, one for positive control containing chlorampheni-
col, RPMI 1640, fluconazole and the fungi, and the other
for negative control containing the fungal isolates, chlor-
amphenicol and RPMI 1640, were included. Each of the
three clinical fungal isolates was tested against Cleome
gynandra ethanol and water extracts and against flucona-
zole. Three tests for ethanol and water extracts of different
concentrations (0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml,
0.0625 mg/ml, 0.0313 mg/ml, 0.0156 mg/ml, 0.00781 mg/
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ml, and 0.00391 mg/ml) were performed to make thirty
(30) tests and the same procedure was applied on the water
extract. The overall number of tests carried out was sixty.
Dissolution of extracts
The dried ethanol and aqueous extracts of C. gynandra
were weighed; 2.0 g of each extract was dissolved in
2 ml of RPMI and made to 1 g/ml. From these solutions,
different strengths of starting concentrations (0.5 mg/ml,
0.25 mg/ml, 0.125 mg/ml, 0.0625 mg/ml, 0.0313 mg/ml,
0.0156 mg/ml, 0.00781 mg/ml, and 0.00391 mg/ml) were
prepared by serial dilutions. These concentrations were
used to test the antifungal activity of C. gynandra to ob-
tain both the minimum inhibitory concentration (MIC)
and the minimum fungicidal concentration (MFC).
Broth dilution method
Two hundred microliters (200 μl) of the confirmed
fungal suspension were drawn each time, added to
each of the test tubes as arranged serially, and mixed
thoroughly. All test tubes contained chloramphenicol
to kill bacterial contaminants. The positive control
test tube had fluconazole (2 mg/ml) and the fungal
isolates. Test tubes with their contents were transferred into
the incubator to incubate between 25–30 °C for 24 h while
observing for turbidity in each test tube, and each time com-
paring each test tube with the positive control and scoring
the turbidity. The turbidity readings were scored numerically
and using codes, for three days (72 h), to determine the
MICs. Turbidity was scored and interpreted as follows [17]:
0 = optically clear/no visible growth, +1 = approximately
25 % growth control, +2 = approximately 50 % growth
control, +3 = approximately 75 % growth control, +4 = no
reduction in growth control.
The procedure was repeated for T. mentagrophytes
and T. rubrum. On the third day a sample of the test
isolates was picked with a cool heat-sterilized wire loop
and subcultured onto SDA slant serially, incubated be-
tween 25–30 °C and observed for aberrant growth (ap-
pearance of filaments) for fourteen days to determine
the MFCs.
Testing of C. gynandra extracts for antifungal activity on
Microsporum canis, Trichophyton mentagrophytes, and
Trichophyton rubrum
Each C. gynandra extract dilution was inoculated with
200 μl of fungal organisms and incubated at 25–30 °C for
24 h. The Microsporum canis (Mc), Trichophyton menta-
grophytes (Tm) and Trichophyton rubrum (Tr) innocula
were each picked separately using a cool heat-sterilized
wire loop, cultivated in RPMI medium, and incubated be-
tween 25–30 °C for three days. MICs were determined by
dermatophyte growth (turbidity) in each test tube while
comparing with the positive control, and were scored
numerically as follows 0 = optically clear/no visible growth,
1 = approximately 25 % growth control, 2 = approximately
50 % growth control, 3 = approximately 75 % growth con-
trol and 4 = very turbid (no reduction in growth control)
according to CLSI, 2008 guidelines [17–19].
Endpoints for determining minimum inhibitory and
minimum fungicidal concentrations
The MIC for dermatophyte was defined as the lowest
drug concentration that inhibited visible growth of the
fungi. The minimal fungicidal concentrations (MFCs) for
dermatophytes were determined by subculturing fungal
isolates from each test tube with no visible growth onto
an SDA slant. The slants were incubated at 30 °C for
14 days while monitoring for fungal growth. The MFC
was defined as the lowest concentration of drug that
yielded a negative subculture [20].
Control tests
Two controls were used for each clinical fungal isolate.
Six positive controls were used, each containing RPMI
1640, chloramphenicol, fluconazole and fungi, and six
other negative controls were also used, each containing
RPMI 1640, chloramphenicol, plus the fungal isolates,
but without the plant extracts. For the positive controls,
one ml of RPMI 1640, 40 μl chloramphenicol (2 g/
10 ml), fluconazole (2 mg/ml), and 200 μl fungi were
added into sterile tubes and mixed to obtain a uniform
mixture. One ml of this mixture was then added onto
the surface of a sterile SDA slant, spread over the
medium, and observed for 14 days for filament growth.
For the negative controls, 200 μl of clinical fungal iso-
lates were added to 1 ml of sterile RPMI 1640 (suspen-
sion) to which an antibacterial agent (chloramphenicol)
was added into a sterile test tube, uniformly mixed, and
incubated at 30 °C for 72 h while observing for turbidity.
Media controls were made by adding the mixture of
RPMI (I ml), chloramphenicol (40 μl), and bacteria
(staphylococcal species), incubating at 30 °C for 72 h in
a sterile test tube; another ml of RPMI 1640 was spread
on SDA slant and uninoculated SDA slant was also incu-
bated at the same temperature (30 °C) for 72 h. Quality
control strain of Candida albicans (ATCC 90028) was
inoculated on SDA, incubated between 25–30 °C, and
purity checked and confirmed from its structural morph-
ology using a gram stain and germ tube. Quality control
was performed using C. albicans every time a positive
control was tested and the extracts and a set of clinical
isolates were evaluated.
Reading of minimum inhibitory and minimum fungicidal
concentrations
MICs of both plant ethanol and water extracts were de-
termined visually from the first day the growth control
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(negative control) showed fungal growth/turbidity, and
72 h later. Growth/turbidity in each test tube was given
a score or code by comparing its contents with those of
the positive control (clear). The MFCs of both ethanol
and water extracts were determined by picking 100 μl of
dermatophyte from each test tube and subculturing this
onto an SDA slant, incubating at 25–30 °C, and visually
observing for filamentous growth on the SDA slants in
all test tubes while comparing with the positive and
negative controls. Growth on each SDA slant was coded
as Fgo where filamentous growth was observed, or as
Nfgo for no filamentous growth observed.
Data analysis
Because of the ordinal nature of the turbidity as an indica-
tor of minimal inhibitory concentrations (expressed as
level of turbidity), we used an ordinal logistic regression
analysis based on fitting a proportional odds model. We
analyzed the effects of the two independent variables (fun-
gal strain and extract), on turbidity (minimum inhibitory
concentrations). Odds ratios-pairwise comparisons of the
categorical variables (fungal strain and ethanol extract)
were also determined. Maximum likelihood estimates
were obtained and shown as p-values. Statistical analysis
was done using SAS® version 9 software.
Ethical considerations
The research proposal was reviewed and approved by the
Faculty Research and Ethics Committee (FREC) and the
Institutional Review Committee (IRC) of Mbarara Univer-
sity (approval numbers are 03/08-12, and MUIRC 1/7, re-
spectively). The hospital administration of Mbarara
Regional Referral Hospital approved the use of the human
clinical fungal isolates, and laboratory rules and protocols
during sensitivity testing were strictly followed.
Results
Percentage yields of the dried extracts were calculated as
weight of dried concentrate divided by the initial weight of
powder ×100; the percentage yield was 23.4 % for the dry
ethanol extract, and 13.3 % for the dry aqueous extract.
Phytochemical screening for constituents of Cleome
gynandra ethanol and water extracts
Phytochemical screening of C. gynandra aerial parts of
both plant extracts indicated the presence of alkaloids, fla-
vonoids, tannins, terpenoids, steroids; however, oils, fats,
and steroids were absent in the water extract, but present
in the ethanolic extract.
Antifungal activity of C. gynandra
MIC readings were determined by reading or observing
levels of turbidity by assigning numbers that were inter-
preted in percentages against the concentrations in milli-
grams/ml (mg/ml). The MICs of the aqueous extract of C.
gynandra against the clinical fungal isolates ranged from
0.0625 to 0.125 mg/ml for T. rubrum and 0.125 to
0.25 mg/ml for both T. mentagrophyte and M. canis
(Fig. 1). For the ethanol extract of Cleome gynandra, MICs
ranged from 0.125 to 0.25 mg/ml for both Microsporum
canis and Trichophyton mentagrophytes, and between
0.0156 to 0.0313 mg/ml for Trichophyton rubrum (Fig. 2).
The aqueous extract of C. gynandra had MFCs of ≥
0.0313 mg/ml for M. canis, ≥0.0156 mg/ml for T.
mentagropyhtes and ≥ 0.0625 mg/ml for T. rubrum dur-
ing the course of 14 days (Table 1). There was filament-
ous growth in the negative control (−ve ctrl) with a
score of +4 corresponding to 100 %, and no filamentous
growth in positive control (+ve ctrl) with score of zero
(Table 1).
Conversely, the MICs of ethanol extract of C. gynan-
dra ranged from 0.125 to 0.25 mg/ml for both M. canis
and T. mentagrophytes and 0.0156 to 0.0313 mg/ml for
T. rubrum (Fig. 2). The MFCs of the ethanol extract of
C. gynandra was ≥ 0.5 mg/ml for M. canis and T.
Fig. 1 MICs of aqueous extract of C. gynandra against the fungal
isolates. Minimum inhibitory concentrations (MICs) of aqueous
extract of Cleome gynandra against the clinical fungal isolates
ranged from 0.0625 to 0.125 mg/ml for Trichophyton rubrum and
0.125 to 0.25 mg/ml for both Trichophyton mentagrophytes and
Microsporum canis. MC = Microsporum canis; TM = Trichophyton
mentagrophytes; and, TR = Trichophyton rubrum
Fig. 2 MICs of ethanol extract of C. gynandra against the fungal
isolates. Minimum inhibitory concentrations (MICs) of ethanol extract
of Cleome gynandra ranged from 0.125 to 0.25 mg/ml for both
Microsporum canis and Trichophyton mentagrophytes and 0.0156 to
0.0313 mg/ml for Trichophyton rubrum; MC = Microsporum canis;
TM = Trichophyton mentagrophytes; and, TR = Trichophyton rubrum
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mentagrophytes, and ≥ 0.125 mg/ml for T. rubrum as a re-
sult of subculturing 200 μl of dermatophytes from each
serially diluted test tube onto SDA slants (Table 2). The
lowest average percentage turbidity was exhibited by the
aqueous and ethanol extracts against T. rubrum, followed
by T. mentagrophyte and finally, M. canis (Table 3).
The variable X1 = (Tr, Mc, and Tm) and dilution had a
statistically significant effect on the outcome (turbidity)
with associated p-values of 0.0083 and <0.0001, respect-
ively. Extract (X2) = (aqueous extract and ethanol ex-
tract) was not found to be statistically significant on the
outcome of turbidity (p = 0.8960). In addition, aqueous
extract was associated 1.1 times (95 % CL 0.27 – 4.55)
with a better outcome compared to ethanol extract al-
though it was not statistically significant. Tr was more
sensitive than Mc (p < 0.002) and more sensitive than
Tm (p < 0.035) to the antifungal activity of C. gynandra.
Tr was also 6.9 times (95 % CL: 1.15 – 41.6) more likely
to have a better outcome (more sensitive) than Tm. Di-
lution had a strongly significant effect on the turbidity
seen as an outcome (p < 0.0001). A summary of the ana-
lysis of maximum likelihood estimates obtained by fit-
ting a proportional odds model is shown in Table 4.
Discussion
The present work was an initial screening study to verify
the ethnomedicinal use of Cleome gynandra L., a plant
used as an antifungal topical treatment for Tinea capitis.
Cleome gynandra is a popular unconventional leafy
vegetable [4, 5, 21] that largely grows wild and is used in
Uganda to treat a variety of ailments including Tinea
capitis [2, 3]. The phytochemical profile of C. gynandra
in our study was similar to that of a recent study [22]
that evaluated the antibacterial activity of C. gynandra
and other plants. In another study, alkaloids, cyanidins,
steroids, and reducing sugars were present in Cleome
gynandra extracts [23] and these secondary metabolites
were indicated to have antifungal activity. Additionally,
phytochemical screening of dried powdered leaves of
Cleome gynandra has shown the presence of flavonoids,
saponins, tannins, sugars, cyanogenetic and cardiac
glycosides, and the absence of anthroquinones and alka-
loids in both ethanol and water plant extracts [24]. As
indicated, the phytochemical analysis of C. gynandra
shoot extracts in the present study demonstrates the
presence of a diverse class of compounds known to have
biological antifungal activities [25, 26].
Safety studies of the plant extracts were not carried
out as mandated for clinical studies, but then the
WHO guidelines, 1996 [27], state “If a product has
been traditionally used without demonstrated harm,
no specific restrictive laboratory action should be
undertaken unless new evidence demands a revised
risk-benefit assessment.” C. gynandra met this criter-
ion, since it is a plant that traditionally is used both
as a vegetable food and as a medicine.
At least one previous preliminary antimicrobial assay
showed poor susceptibility of Candida albicans to inhib-
ition or to the killing effect of a qualitative crude metha-
nolic extract of Cleome gynandra [6]. The results
obtained in our study, however, for the minimum inhibi-
tory concentrations and for the minimum fungicidal
Table 1 MFCs of aqueous extract of C. gynandra against the fungal isolates
Fungi Minimum fungicidal concentrations of aqueous extract of Cleome gynandra in mg/ml Controls
0.5 0.25 0.125 0.0625 0.0313 0.0156 0.00781 0.00391 -ve ctrl +ve ctrl
Mc Nfgo Nfgo Nfgo Nfgo Nfgo Fgo Fgo Fgo Fgo Nfgo
Tm Nfgo Nfgo Nfgo Nfgo Nfgo Nfgo Fgo Fgo Fgo Nfgo
Tr Nfgo Nfgo Nfgo Nfgo Fgo Fgo Fgo Fgo Fgo Nfgo
Fgo denotes that filamentous growth was observed, while Nfgo denotes that no filamentous growth was observed. The results obtained during the course of 14
days revealed that the water extract of Cleome gynandra had MFCs of ≥ 0.0313 mg/ml for Microsporum canis, ≥0.0156 mg/ml for Trichophyton mentagrophytes
and ≥ 0.0625 mg/ml for Trichophyton rubrum. There was filamentous growth in the negative control (- ve ctrl) with a score of +4, corresponding to 100%, and no
filamentous growth in positive control (+ve ctrl), with a score of zero (0). Mc = Microsporum canis; Tm = Trichophyton mentagrophytes; and, Tr = Trichophyton
rubrum
Table 2 MFCs of ethanol extract of C. gynandra against the fungal isolates
Fungi Minimum fungicidal concentrations of ethanol extract of Cleome gynandra in mg/ml Controls
0.5 0.25 0.125 0.0625 0.0313 0.0156 0.00781 0.00391 −ve ctrl + ctrl
Mc Nfgo Fgo Fgo Fgo Fgo Fgo Fgo Fgo Fgo Nfgo
Tm Nfgo Fgo Fgo Fgo Fgo Fgo Fgo Fgo Fgo Nfgo
Tr Nfgo Nfgo Nfgo Fgo Fgo Fgo Fgo Fgo Fgo Nfgo
Fgo denotes that filamentous growth was observed, while Nfgo denotes that no filamentous growth was observed. The ethanol extract of Cleome gynandra
indicated MFCs of ≥ 0.5 mg/ml for Microsporum canis and Trichophyton mentagrophytes, and ≥ 0.125 mg/ml for Trichophyton rubrum as result of subculturing
200 µl of dermatophytes from each serially diluted test tubes onto SDA slants. Mc = Microsporum canis; Tm = Trichophyton mentagrophytes; and, Tr = Trichophyton
rubrum
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concentrations, suggest that C. gynandra extracts pos-
sess antifungal activity. It is possible that the difference
in activity described for the study that showed weak ac-
tivity of C. gynandra extract and our study was because
of the difference in the amount of active principles ex-
tracted, as well as the type of organism. MICs of both
aqueous and ethanolic extracts ranged from 0.0313 to
0.5 mg/ml. There was a systematic trend of antifungal
activity displayed by C. gynandra ethanol extract against
the clinical fungal isolates. T. rubrum was most sensitive
to both extracts followed by T. mentagrophytes, and least
by M. canis. The water extract exhibited the lowest
MFCs ranging from 0.0313 – 0.0625 mg/ml for M. canis,
0.0156 – 0.0313 mg/ml for T. mentagrophytes, and
0.0625 – 0.125 mg/ml for T. rubrum.
On the basis of the MICs obtained, the fungal isolates
were generally sensitive to both the ethanol extract and
the aqueous extract. Studies on other plants with anti-
fungal activity have reported antifungal activities of alka-
loids and flavonoids [23, 28], which were also present in
the two extracts used in this study. The comparable an-
tifungal activity of the water and ethanol extracts in this
study suggests that the concentrations of the active me-
tabolites extracted by the two solvents is not reduced by
using water which yielded less extract than ethanol, and
considering that the aqueous extract lacked oils, fats and
steroids. This study has demonstrated that Cleome
gynandra possesses antifungal activity and adds to the
body of existing knowledge about this plant.
The present study was limited, however, in that it was
an in vitro study, not an in vivo one. In addition, antifun-
gal activity was evaluated on clinical isolates that already
could have had prior exposure to conventional antifungal
drugs. It is conceivable therefore, that Cleome gynandra
extracts would have greater antifungal effect than was
seen in this study. Lastly, in vitro testing to determine the
end-points of MIC and MFC in the present study was for
14 days; however, in traditional medicinal use the plant
leaves are applied topically as a remedy until the symp-
toms of Tinea capitis disappear, not necessarily for only
14 days. Future studies shall address the antifungal efficacy
of Cleome gynandra extracts on T. capitis and other fun-
gal conditions, through clinical trials comparing these ex-
tracts to standard antifungal agents.
Conclusion
Both plant extracts demonstrated antifungal activity. An-
tifungal activity of the two plant extracts varied with the
type of organism of the clinical fungal isolates. The etha-
nol extract showed comparable antifungal activity to the
aqueous extract. There is need to develop new antifungal
drugs that are cheap, accessible, safe and efficacious.
Further quantitative studies should be done to determine
the efficacy of specific active phytochemicals and exact
concentrations of specified extracts per species of
dermatophytes.
Abbreviations
ATCC, American Type Culture Collection; CLSI, Clinical and Laboratory
Standards Institute; Fgo, fungal growth; MFC, minimum fungicidal
concentration; MIC, minimum inhibitory concentration; Nfgo, no fungal
growth; RPMI, Roswell Park Memorial Institute; SDA, Sabouraud Dextrose
Agar.
Table 3 Percentage turbidity (mean) of aqueous and ethanol extracts against M. canis, T. mentagrophytes, and T. rubrum
Aqueous extract Ethanol extract
Dilution (mg/ml) Mc Tm Tr Mc Tm Tr
0.125 50 50 0 50 25 0
0.0625 50 50 25 50 50 0
0.0313 75 50 50 100 50 0
0.0156 75 50 50 100 75 50
0.00781 100 100 100 100 100 100
0.00391 100 100 100 100 100 100
The lowest average percentage turbidity was exhibited by the aqueous and ethanol extracts against Trichophyton rubrum, followed by Trichophyton
mentagrophytes, and finally Microsporum canis. Mc = Microsporum canis; Tm = Trichophyton mentagrophytes; and, Tr = Trichophyton rubrum. The cell entries
(0-100) indicate the percentage turbidities (a measure of fungal growth of the three strains Mc, Tm and Tr), resulting from the effect of the two extracts at the
corresponding dilutions. All tests were done in triplicate
Table 4 Mc, and Tm are compared to Tr and the aqueous
extract is compared to ethanol extract when the model is fitted.
Tr was more sensitive than Mc (p<0.002) and more sensitive
than Tm (p<0.035) to the antifungal activity of C. gynandra.
Comparing the aqueous extract and ethanol extract, there was
no statistically significant difference in the effect of extract on
fungal strains (p=0.8960). However, dilution had a strongly
significant effect on the outcome (p<0.0001)
Parameter Estimate Standard Error Wald Chi-Square P-value
Mc 3.16 1.03 9.38 0.002*
Tm 1.93 0.92 4.47 0.035*
Aqueous extract −0.10 0.72 0.02 0.896
Dilution −57.11 14.32 15.90 <0.0001*
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